Eprosartan: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m molar mass: correct unit (should be g/mol). No need to link SI units (via AWB script)
 
(20 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|Angiotensin II receptor antagonist}}
{{Drugbox
{{Drugbox
| Watchedfields = changed
| Watchedfields = changed
| verifiedrevid = 461094389
| verifiedrevid = 461094389
⚫
| IUPAC_name = 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1''H''-imidazol-1-yl}methyl)benzoic acid
| image = Eprosartan.svg
| image = Eprosartan.svg

<!--Clinical data-->
<!--Clinical data-->
| tradename = Teveten
| tradename = Teveten
| Drugs.com = {{drugs.com|monograph|teveten}}
| Drugs.com = {{drugs.com|monograph|teveten}}
| MedlinePlus = a601237
| MedlinePlus = a601237
| DailyMedID = Eprosartan
⚫
| pregnancy_category =
| legal_status =
| pregnancy_AU = D
| pregnancy_AU_comment =
⚫
| routes_of_administration = Oral
⚫
| pregnancy_category=
⚫
<!--Pharmacokinetic data-->
⚫
| routes_of_administration = [[Oral administration|By mouth]]
⚫
| ATC_prefix = C09
⚫
| ATC_suffix = CA02

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = <!-- For countries not listed above -->

⚫
<!-- Pharmacokinetic data -->
| bioavailability = 15% (Eprosartan mesylate)
| bioavailability = 15% (Eprosartan mesylate)
| metabolism = not metabolized
| metabolism = not metabolized
| elimination_half-life = 5 to 9 hours
| elimination_half-life = 5 to 9 hours
| excretion = [[Renal]] 10%, [[biliary]] 90%
| excretion = [[Kidney]] 10%, [[bile duct]] 90%

<!--Identifiers-->
<!--Identifiers-->
| index2_label = as mesylate
| IUPHAR_ligand = 588
| IUPHAR_ligand = 588
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 133040-01-4
| CAS_number = 133040-01-4
⚫
| ATC_prefix = C09
⚫
| ATC_suffix = CA02
| PubChem = 5281037
| PubChem = 5281037
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
Line 31: Line 58:
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04040
| KEGG = D04040
| KEGG2_Ref = {{keggcite|correct|kegg}}
| KEGG2 = D02082
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4814
| ChEBI = 4814
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 813
| ChEMBL = 813

<!--Chemical data-->
<!--Chemical data-->
⚫
| IUPAC_name = 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1''H''-imidazol-1-yl}methyl)benzoic acid
| C=23 | H=24 | N=2 | O=4 | S=1
| C=23 | H=24 | N=2 | O=4 | S=1
| molecular_weight = Eprosartan mesylate: 520.625 g/mol
| SMILES = O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
| SMILES = O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
| InChI = 1/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
| InChIKey = OROAFUQRIXKEMV-LDADJPATBR
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
| StdInChI = 1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
Line 47: Line 75:
}}
}}


'''Eprosartan''', sold under the brand name '''Teveten''' among others, is an [[angiotensin II receptor antagonist]] used for the treatment of [[hypertension|high blood pressure]].<ref>{{cite web | title=Eprosartan mesylate- eprosartan mesylate tablet, film coated | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=475394 | access-date=7 June 2023}}</ref>
⚫
'''Eprosartan''' is an [[angiotensin II receptor antagonist]] used for the treatment of [[hypertension|high blood pressure]]. It is marketed in the [[United States]] as ''Teveten'' by [[Abbvie]], the [[Corporate spin-off|spin-off]] of the pharmaceutical discovery division of [[Abbott Laboratories]]; it is marketed as ''Eprozar'' by [[INTAS Pharmaceuticals]] in [[India]], and by [[Abbott Laboratories]] elsewhere. The compound came into the [[Abbott Laboratories]] cardiovascular pipeline with its acquisition of [[Kos Pharmaceuticals]] in 2006, which had licensed it, along with "a range of hypertensive treatments", from the [[Biovail Corporation]].<ref>Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [http://www.datamonitor.com/store/News/abbott_laboratories_kos_pharmaceuticals_a_wise_buy?productid=0BE8B1AB-14F9-4B92-99D2-80E8DC7ECA16], accessed 29 January 2015.</ref>

Eprosartan is sometimes paired with [[hydrochlorothiazide]], whereupon it is marketed in the US as '''Teveten''' '''HCT''' and elsewhere as '''Teveten''' '''Plus'''.'''

The drug acts on the [[renin-angiotensin system]] to decrease [[total peripheral resistance]] in two ways. First, it blocks the binding of [[angiotensin II]] to AT<sub>1</sub> receptors in vascular [[smooth muscle]], causing vascular dilatation. Second, it inhibits [[sympathetic nervous system|sympathetic]] [[norepinephrine]] production, further reducing blood pressure.

⚫
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than [[enalapril]] (an [[ACE inhibitor]]), especially among the elderly.<ref>{{cite journal |author=Ruilope L, Jäger B, Prichard B |title=Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial |journal=Blood Press. |volume=10 |issue=4 |pages=223–9 |year=2001 |pmid=11800061 |doi=10.1080/08037050152669747}}</ref>


Eprosartan is sometimes paired with [[hydrochlorothiazide]].<ref>{{cite web | title=Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet | website=DailyMed | date=3 January 2012 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1dfcac3-ef66-4d3e-9d58-37d3f516eb31 | access-date=7 June 2023}}</ref>
== See also ==


⚫
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than [[enalapril]] (an [[ACE inhibitor]]), especially among the elderly.<ref>{{cite journal |vauthors=Ruilope L, Jäger B, Prichard B |title=Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial |journal=Blood Press. |volume=10 |issue=4 |pages=223–9 |year=2001 |pmid=11800061 |doi=10.1080/08037050152669747|s2cid=13063704 |doi-access=free }}</ref>
* [[Discovery and development of angiotensin receptor blockers]]


==References==
== History ==
⚫
The compound came into the [[Abbott Laboratories]] cardiovascular pipeline with its acquisition of [[Kos Pharmaceuticals]] in 2006, which had licensed it, along with "a range of hypertensive treatments", from the [[Biovail Corporation]].<ref>Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [http://www.datamonitor.com/store/News/abbott_laboratories_kos_pharmaceuticals_a_wise_buy?productid=0BE8B1AB-14F9-4B92-99D2-80E8DC7ECA16], accessed 29 January 2015.</ref>
<references/>


==External links==
== References ==
{{reflist}}


{{Angiotensin II receptor antagonists}}
{{Angiotensin II receptor antagonists}}
{{Angiotensin receptor modulators}}
{{Peptidergics}}
{{Portal bar | Medicine}}


[[Category:Angiotensin II receptor antagonists]]
[[Category:Angiotensin II receptor antagonists]]
[[Category:Imidazoles]]
[[Category:Imidazoles]]
[[Category:Thiophenes]]
[[Category:Thiophenes]]
[[Category:Drugs developed by AbbVie]]
[[Category:Benzoic acids]]
[[Category:Benzoic acids]]

Latest revision as of 19:27, 20 December 2023

Eprosartan
Clinical data
Trade namesTeveten
AHFS/Drugs.comMonograph
MedlinePlusa601237
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability15% (Eprosartan mesylate)
Metabolismnot metabolized
Elimination half-life5 to 9 hours
ExcretionKidney 10%, bile duct 90%
Identifiers
  • 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H24N2O4S
Molar mass424.52 g·mol−1
3D model (JSmol)
  • O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
  • InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ checkY
  • Key:OROAFUQRIXKEMV-LDADJPATSA-N checkY
  (verify)

Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.[1]

Eprosartan is sometimes paired with hydrochlorothiazide.[2]

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[3]

History[edit]

The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[4]

References[edit]

  1. ^ "Eprosartan mesylate- eprosartan mesylate tablet, film coated". DailyMed. Retrieved 7 June 2023.
  2. ^ "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet". DailyMed. 3 January 2012. Retrieved 7 June 2023.
  3. ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. S2CID 13063704.
  4. ^ Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [1], accessed 29 January 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Eprosartan&oldid=1190943533"